New drug combination for children with recurring lymphoma

Plain-English translation of NCT07013565 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether combining brentuximab vedotin (a targeted antibody medicine) with nivolumab (an immune-boosting medication) can help treat anaplastic large cell lymphoma that has returned after initial treatment. Both medicines work in different ways — one targets cancer cells directly, while the other helps your immune system fight the cancer. The trial aims to see if using them together is safe and more effective than previous treatments.

Standard chemotherapy has not been able to prevent about 20–30% of patients with this type of lymphoma from having their cancer come back or progress. Recent research shows that this medication combination has worked well in other types of lymphoma and may be promising for this specific type, especially since cancer cells in this disease express the targets that both medications attack.

Do you qualify?

You likely qualify if…

you have been diagnosed with anaplastic large cell lymphoma (a specific type of blood cancer) that is ALK-positive
your lymphoma has come back after initial treatment or did not fully respond to initial treatment
you weigh at least 10 kilograms (about 22 pounds)
your organs are functioning well enough to safely receive the treatment
you are well enough to participate in the trial (score of 60 or higher on a standard activity scale)

You likely don't qualify if…

you have ALK-negative anaplastic large cell lymphoma (a different form of the disease)
you have lymphoma cells in your spinal fluid (active leptomeningeal disease)
you are pregnant, breastfeeding, or trying to become pregnant
you have an active infection that is not controlled before starting the trial
you have Down syndrome or a weakened immune system, or have received a solid organ transplant

What participation looks like

Depending on whether you are classified as lower-risk or higher-risk based on your specific disease characteristics, you will receive the medication combination through infusions and possibly other chemotherapy medicines at a cancer center. The treatment plan is customized based on your individual risk factors, and you will have regular visits for monitoring, blood tests, and scans to check how well the treatment is working and to watch for side effects. The trial is designed to help researchers understand the best way to use this medication combination to treat your type of lymphoma.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(1 site)

United States

New York Medical College, Valhalla, New York